Recurrent abortion combined with reduced ovarian reserve function
Conditions
Interventions
Test group:Gekang Oral Liquid + Estradiol Tablets/Estradiol Diprogesterone Tablets Composite Packaging (Fenmatong)
Control group:Pregnancy oral liquid simulator + estradiol tablets/estradiol diprogesterone tablets compound packaging (fenmotong)
Sponsors
eking University Third Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for recurrent abortion; 2. Meet the diagnostic criteria for reduced ovarian reserve function; 3. Those who are 3 months old from the last abortion are currently in the pregnancy preparation stage; 4. It conforms to the syndrome differentiation standards of traditional Chinese medicine for kidney deficiency syndrome and qi and blood weakness syndrome. 5. 20-45 years old; 6. Voluntaryly participate in this clinical trial give informed consent and sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Combine other reproductive internal divisions that affect the function of ovarian reserve or the evaluation of drug effectiveness Diseases of the urinary or metabolic immune system; 2. Chromosomal abnormalities enzyme defects (such as galactosemia etc.) tumors or due to surgery (such as eggs) Nest surgery uterine artery ligation tubal resection etc.) radiotherapy chemotherapy and other doctors Decreased ovarian reserve function caused by source factors; 3. Patients with serious diseases such as cardiovascular and cerebrovascular liver kidney hematopoiesis etc.; 4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)> 1.5 times the upper limit of normal reference value blood creatinine (Scr) > upper limit of normal reference value; 5. Pregnant or lactating women; 6. Known allergies or contraindications to experimental drugs; 7. Received Chinese and Western drugs for the treatment of ovarian reserve function within 1 month before joining the group; 8. Participated in other clinical trials within 3 months before randomization; 9. The researchers believe that it is not appropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Week 12 follicle-stimulant (FSH) change value; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change value of anti-Müller tube hormone (AMH) in the 12th week;Disappearing rate of individual symptoms in Week 12;Clinical pregnancy rate during the trial;Changes in sinus follicle count (AFC) in the 12th week;Clinical pregnancy time;The incidence of early pregnancy abortion;The change value and efficiency of the score of traditional Chinese medicine syndrome in the 12th week; | — |
Countries
China
Contacts
Public ContactLi Rong
eking University Third Hospital
Outcome results
None listed